Average Insider

Where insiders trade, we follow

$CUE
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Usman Azam
CEO
41
Employees
$17.50
Current Price
$23.65M
Market Cap
52W Low$4.97
Current$17.5030.9% above low, 69.1% below high
52W High$45.50

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00---
Sells00--
1 monthBuys00---
Sells00--
2 monthsBuys00--All Sells
Sells34$389,303.7514,075
3 monthsBuys00--All Sells
Sells34$389,303.7514,075
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Oct 12, 2026
Ray Sumita
Chief Legal Compliance Officer
Sale1,844$28.05$51,724.20View Details
Oct 12, 2026
Meluzio Michael Vincent
VP, Prin. Accounting Officer
Sale1,144$28.05$32,089.20View Details
Oct 12, 2026
Lin Shao-Lee
Director
Sale1,087$28.05$30,490.35View Details
Oct 12, 2026
Lin Shao-Lee
Director
Sale10,000$27.50$275,000.00View Details
16 more transactions available โ€” create a free account to see 12 months of history

Upcoming Earnings

Scheduled earnings reports
Nov 18, 2026
EPS
Estimated-$2.24
ActualN/A
Revenue
Estimated$1.03M
ActualN/A

Past Earnings

Historical earnings results
Nov 16, 2026
EPS
Estimated-$2.24
Actual-$4.74
Miss
Revenue
Estimated$1.03M
Actual$132.00K
Miss
Nov 11, 2026
EPS
Estimated-$2.24
ActualN/A
Revenue
Estimated$1.03M
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1